We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 42.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
76
DELISTED
Zogenix, Inc.
ZGNX
$3.22M 0.03%
293,800
– –
SGYP
77
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$2.97M 0.03%
973,245
– –
RCPT
78
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.93M 0.03%
23,900
– –
APTO
79
DELISTED
Aptose Biosciences, Inc.
APTO
$2.83M 0.03%
+1,065
New +$3.2M
FMI
80
DELISTED
Foundation Medicine, Inc.
FMI
$2.8M 0.03%
126,147
+47,985
+61% +$1.11M
SAGE
81
DELISTED
Sage Therapeutics
SAGE
$2.75M 0.03%
75,000
– –
SVRA icon
82
Savara
SVRA
$1.09B
$2.67M 0.03%
68,206
+25,349
+59% +$885K
LPCN icon
83
Lipocine
LPCN
$17.1M
$2.63M 0.03%
29,412
– –
AUPH icon
84
Aurinia Pharmaceuticals
AUPH
$1.94B
$2.6M 0.03%
727,669
– –
BDSI
85
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.52M 0.03%
210,021
– –
AFMD
86
DELISTED
Affimed
AFMD
$2.48M 0.03%
40,000
– –
VXRT
87
DELISTED
Vaxart
VXRT
$2.48M 0.03%
100,628
– –
OSUR icon
88
OraSure Technologies
OSUR
$273M
$2.38M 0.02%
234,664
– –
MRNS
89
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$2.16M 0.02%
51,119
– –
DERM
90
DELISTED
Dermira, Inc.
DERM
$1.81M 0.02%
+100,000
New +$1.67M
TARA icon
91
Protara Therapeutics
TARA
$215M
$1.8M 0.02%
+4,323
New +$1.74M
ISEE
92
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.65M 0.02%
36,776
– –
MDWD icon
93
MediWound
MDWD
$186M
$1.5M 0.02%
32,143
– –
PTN
94
Palatin Technologies
PTN
$14.1M
$1.5M 0.02%
+1,640
New +$1.51M
MDGL icon
95
Madrigal Pharmaceuticals
MDGL
$12.5B
$1.32M 0.01%
14,286
– –
GERN icon
96
Geron
GERN
$924M
$1.31M 0.01%
402,629
– –
AKAO
97
DELISTED
Achaogen Inc
AKAO
$1.3M 0.01%
100,000
– –
LOXO
98
DELISTED
Loxo Oncology, Inc
LOXO
$1.18M 0.01%
100,000
– –
TSRO
99
DELISTED
TESARO, Inc.
TSRO
$1.16M 0.01%
31,218
– –
ALNY icon
100
Alnylam Pharmaceuticals
ALNY
$38.2B
$1.13M 0.01%
11,600
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Baker Bros. Advisors held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Baker Bros. Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Baker Bros. Advisors added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Baker Bros. Advisors's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Baker Bros. Advisors fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Baker Bros. Advisors opened 14 new positions and closed 2 in Q4 2014.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.